These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1612854)

  • 21. [The significance of erythropoietin for nephrology].
    Watzinger U; Peer G; Barnas U; Mayer G; Luger A; Kovarik J; Graf H
    Wien Klin Wochenschr; 1990 Mar; 102(5):125-30. PubMed ID: 2181782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients.
    Altun B; Erdem Y; Haznedaroğlu I; Gürsoy M; Yasavul U; Turgan C; Cağlar S; Kirazli S
    Nephrol Dial Transplant; 1995 Nov; 10(11):2164. PubMed ID: 8643199
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
    Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
    Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
    Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of indicators of erythropoiesis stimulated by recombinant human erythropoietin in renal anemia.
    Schmidt G; Stamminger G; Daniel A; Gross J; Syllm-Rapoport I; Lun A; Zoellner K
    Biomed Biochim Acta; 1990; 49(2-3):S275-9. PubMed ID: 2386517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
    Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA
    Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Status epilepticus in chronically dialyzed patients treated with erythropoietin].
    Massetani R; Galli R; Calabrese R; Sartucci F; Rindi P; Severino Brandi L; Murri L
    Riv Neurol; 1991; 61(6):215-8. PubMed ID: 1813973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Erythropoietin].
    Uhl D
    Med Monatsschr Pharm; 1990 May; 13(5):130-1. PubMed ID: 2192242
    [No Abstract]   [Full Text] [Related]  

  • 31. Biological characterization of recombinant human erythropoietin.
    Krumwieh D; Arnold I; Seiler FR
    Behring Inst Mitt; 1988 Aug; (83):193-201. PubMed ID: 3240225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Setting up an 'EPO' system. Management of patients receiving recombinant human erythropoietin.
    Brown SM
    Prof Nurse; 1992 Feb; 7(5):282-3, 286-7. PubMed ID: 1738775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seizures in dialysis patients treated with recombinant erythropoietin.
    Beccari M; Romagnoni M; Sorgato G
    Nephrol Dial Transplant; 1995; 10(3):423-4. PubMed ID: 7792048
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 35. [Erythropoietin: its biological properties and clinical use].
    Ermolenko VM; Nikolaev AIu
    Ter Arkh; 1990; 62(11):141-5. PubMed ID: 2094979
    [No Abstract]   [Full Text] [Related]  

  • 36. [Cutaneous reactions to treatment with recombinant human erythropoietin].
    Schröder-Kolb B
    Derm Beruf Umwelt; 1990; 38(1):12-3. PubMed ID: 2139602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of recombinant human erythropoietin during hemodialysis on the thrombocyte and erythrocyte functions of patients with chronic kidney failure].
    Rud'ko IA; Balashova TS; Kubatiev AA; Ermolenko VM
    Ter Arkh; 1994; 66(6):57-60. PubMed ID: 7940371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human erythropoietin. Experimental and clinical applications.
    Nielsen OJ
    Dan Med Bull; 1991 Oct; 38(5):355-70. PubMed ID: 1802621
    [No Abstract]   [Full Text] [Related]  

  • 39. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
    Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A multicenter trial of Recormon within the framework of international controlled research].
    Tareeva IE; Nikolaev AIu; Klepikov PV; Lashutin SV; Riabov SI; Shostka GD; Ermolenko VM; Rozental' RL; Vorob'ev PA; Miagkov AV
    Ter Arkh; 1992; 64(8):59-62. PubMed ID: 1440400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.